Dr.

Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills,

Hyderabad 500034, India.
www.drreddys.com

ABOUT:
Dr. Reddy's Laboratories, headquartered in Hyderabad, India, stands as a
formidable force in the global pharmaceutical industry. Founded by Kallam
Anji Reddy, whose background at the Indian Drugs and Pharmaceuticals
Limited laid the foundation for a remarkable journey, the company has
become a powerhouse in healthcare.
Their extensive product range spans over 190 medications, 60 active
pharmaceutical ingredients (APIs) for drug manufacturing, diagnostic kits,
critical care essentials, and a significant presence in biotechnology. Dr.
Reddy's commitment to diverse healthcare solutions is evident.
What sets Dr. Reddy's apart is its strategic expansion into less-regulated
markets early on, allowing them to swiftly scale operations and build
profitability. This agility enabled them to shift focus to more developed
markets, gaining approvals from stringent regulatory bodies like the U.S. Food
and Drug Administration (FDA) for entry into regulated regions, including the
United States and Europe.
With a global network of FDA-approved facilities for API production in India
and ISO-certified plants for patient-ready medications, including operations in
the UK.
HISTORY
 Dr. Reddy's Laboratories, founded in 1984, has evolved significantly
since its inception. It started by producing active pharmaceutical
ingredients and later ventured into branded formulations.

 In 1992, Dr. Reddy's made its international debut in Russia through a

joint venture with Biomed. However, this venture ended in 1995 amid
controversy. The company expanded into the Middle East and the USA,
focusing on generics and active pharmaceutical ingredients.

 Dr. Reddy's emphasized specialty generics as a foundation for drug

discovery. It invested heavily in research and established labs, including
one in the U.S., dedicated to genomics and proteomics for next-
generation drugs.
 By 1997, the company transitioned into generics and acquired American
Remedies Ltd., becoming one of India's top pharmaceutical companies.
 Dr. Reddy's also embraced Para 4 filing as a strategy to expedite new
drug launches.
 American IPO and European Expansion In 2001, Dr. Reddy's completed
a successful IPO in the U.S., enabling international production and
technology-based acquisitions.
 The company invested in Bio Sciences Ltd. and established Auriegene
Discovery Technologies for contract research.
 Dr. Reddy's acquired BMS Laboratories in the UK and partnered with
Argenta Discovery for COPD treatment. It also signed agreements for
diabetes and cardiovascular drug development.

 In 2004, the company expanded into dermatology with the acquisition

of Trigenesis Therapeutics Inc. Challenges and Successes The company
faced challenges in patent litigation, but it successfully launched
generics like fluoxetine (a generic version of Prozac) in the U.S. This
move was followed by the launch of house-branded ibuprofen tablets.
  As of 2006, Dr. Reddy's Laboratories exceeded $500 million in revenues,
with APIs and branded formulations contributing significantly.
 In 2015, Dr. Reddy's acquired established brands from Belgian drug
maker UCB SA in South Asia. It also signed a licensing pact for an
experimental treatment for plaque psoriasis.
 In 2016, Dr. Reddy's launched "Purple Health," a patient-centric
platform addressing awareness, access, adherence, and experience in
medication.
 COVID-19 Involvement In 2020, the company partnered with the
Russian Direct Investment Fund to conduct Sputnik V COVID-19 vaccine
trials in India and manufacture up to 100 million doses.

ECONOMIC ASPETS OF DR.REDDY’S LABORATORIES:

In the fiscal year 2023, Dr. Reddy's Laboratories achieved a significant
milestone by demonstrating exceptional financial performance and growth.
Their revenue soared to an impressive ₹25,725 crore, equivalent to
approximately US$3.2 billion, underscoring the company's remarkable ability
to generate substantial income across its diverse pharmaceutical operations.
This substantial revenue increase was accompanied by a robust operating
income of ₹6,011 crore, or approximately US$750 million, a testament to their
solid profitability even after accounting for operating expenses. The net
income for the same period reached a substantial ₹4,470 crore, roughly
equivalent to US$560 million, highlighting the company's strong financial
health and efficiency in managing expenses and taxes.
Dr. Reddy's Laboratories also reported a noteworthy expansion in its total
assets, which amounted to ₹23,156 crore, or approximately US$2.9 billion,
demonstrating the company's financial strength and the value of its overall
asset base. Furthermore, the company's total equity surged to ₹23,286 crore,
or approximately US$2.9 billion, exemplifying its robust net worth and
financial stability.
With an extensive workforce comprising 21,650 employees as of March 2020,
Dr. Reddy's Laboratories remains a global leader in the pharmaceutical
industry, dedicated to delivering innovative healthcare solutions and driving
economic growth while maintaining its commitment to excellence and
expansion in the ever-evolving pharmaceutical landscape.
In 2023, Dr. Reddy's Laboratories, headquartered in Hyderabad, India,
reported impressive financial figures. The company's revenue stood at 25,725
crore (US$3.2 billion), demonstrating its strong market presence. Operating
income reached 6,011 crore (US$750 million), showcasing robust operational
efficiency. Dr. Reddy's Laboratories achieved a net income of 4,470 crore
(US$560 million), indicating solid profitability.
With total assets valued at 23,156 crore (US$2.9 billion) and total equity of
23,286 crore (US$2.9 billion) in 2023, the company displayed a strong
financial foundation. As of March 2020, Dr. Reddy's Laboratories boasted a
workforce of 21,650 employees, reflecting its significant role as a major
employer. These figures underscore the company's prominent position in the
pharmaceutical industry and its continued growth and success.
 Revenue 25,725 crore (US$3.2 billion) (2023)
Operating income 6,011 crore (US$750 million) (2023)

Net income 4,470 crore (US$560 million) (2023)

Total assets 23,156 crore (US$2.9 billion)

Total equity 23,286 crore (US$2.9 billion) (2023)

Number of employees21,650 (March 2020)[1]

RESEARCH AND DEVELOPMENT:

 In the United Kingdom, Dr. Reddy's Laboratories (UK) Limited and Dr. Reddy's
Laboratories (EU) Limited stand as beacons of pharmaceutical research
excellence. Their addresses, 6, Riverview Road, Beverley, East Yorkshire, HU17
OLD, and Steanard Lane, Mirfield, West Yorkshire, WF14 8HZ, respectively, are
hubs of innovation in Europe. These centers facilitate cutting-edge research
and development activities, bolstering the company's presence on the
continent.

 Additionally, Chirotech Technology Limited, located at 410 Cambridge Science

Park, Milton Road, Cambridge, CB4 0PE, significantly contributes to organic
synthesis and process research.

 Innovation In the Netherlands, the Technology Development Centre Leiden

Octoplus N.V., situated at Zernikedreef 12, 2333 CL Leiden, is a key facility for
Dr. Reddy's Laboratories. This center plays a vital role in pioneering
 pharmaceutical research and development, contributing to the company's
global research initiatives.

 The United States hosts several crucial R&D locations for Dr. Reddy's
Laboratories. Dr. Reddy's Laboratories Tennessee LLC, located at P.O. Box
9002, 201 Industrial Drive, Bristol, Tennessee 37621-9002, USA, serves as a
central hub for pharmaceutical research, contributing to the company's
presence in North America.

 Dr. Reddy's Laboratories New York Inc., with its address at 1974 Route 145,
P.O. Box 500, Middleburgh, New York 12122, USA, is another key player in the
company's global innovation endeavors.
 Moreover, the Technology Development Centre in Princeton, New Jersey,
marked by its address, 303 College Road East, Princeton, New Jersey 08540,
USA, serves as a strategic location for research and development initiatives.

 In, India, Dr. Reddy's Laboratories boasts a network of API (Active

Pharmaceutical Ingredient) plants dedicated to research and development.
These facilities, including those in Hyderabad, Nalgonda, and Srikakulam, are
instrumental in pioneering pharmaceutical research and development in the
region.
 Their addresses are as follows: API Hyderabad Plant 1: Plot No. 137 & 138, IDA
Bollaram, Jinnaram Mandal, Medak District, Telangana 502 325, INDIA.

 API Hyderabad Plant 2: Plot No. 75B, 105, 110 & 111, IDA Bollaram, Jinnaram
Mandal, Medak District, Telangana 502 325, INDIA.

 API Hyderabad 3: Plot No. 116, 116A & 126C & SY No. 157, IDA Bollaram,
Jinnaram Mandal, Medak District, Telangana 502 325, INDIA. API Hyderabad
Plant 4: Plot No. 9/A, 9/B, 22A, 22B & 22C, Phase – III, IDA Jeedimetla, Ranga
Reddy District, Telangana 500 055, INDIA.

 API Nalgonda Plant: Peddadevulapally, Tripuraram Mandal, Nalgonda District,

Telangana 508 207, INDIA. API Srikakulam Plant: IDA Pydibheemavaram,
Ransthal Mandal, Srikakulam District, Andhra Pradesh 532 409, INDIA.

 These R&D centers collectively form a formidable global network of

innovation, underscoring Dr. Reddy's Laboratories' dedication to pioneering
 healthcare solutions, driving economic growth, and contributing to
pharmaceutical excellence on a worldwide scale.

MANUFACTURING FACILITIES OF THE COMPANY:

Manufacturing Plants Asia and Europe

 In China, Kunshan Rotam Reddy Pharmaceutical Co. Limited stands tall as one of
Dr. Reddy's manufacturing hubs. Located at No. 258, Huang Pu Jiang (M) Road,
Kunshan Development Zone, Jiangsu Province 215 300, P.R. CHINA, this facility is
a testament to the company's commitment to quality and innovation.
 India hosts several key manufacturing plants for Dr. Reddy's Laboratories. The
API (Active Pharmaceutical Ingredient) manufacturing plants are strategically
located to ensure efficient production. API Hyderabad Plant 1, with its address at
Plot No. 137 & 138, IDA Bollaram, Jinnaram Mandal, Medak District, Telangana
502 325, INDIA, is a cornerstone of the company's operations.
 Its state-of-the-art facilities contribute to the production of vital pharmaceutical
ingredients.
 The API Nalgonda Plant, situated in Peddadevulapally, Tripuraram Mandal,
Nalgonda District, Telangana 508 207, INDIA, is another essential component of
Dr. Reddy's manufacturing prowess. Its role in ensuring the availability of critical
pharmaceutical ingredients cannot be overstated.
 Further south, the API Srikakulam Plant, located at IDA Pydibheemavaram,
Ransthal Mandal, Srikakulam District, Andhra Pradesh 532 409, INDIA, plays a
vital role in supporting the company's manufacturing capabilities in the region.
 Additionally, the API Srikakulam Plant (SEZ), in Sector No. 28 & 34,
Devunipalavalasa Village, Ranastalam Mandal, Srikakulam District, Andhra
Pradesh 532 409, INDIA, adds to the company's capacity for pharmaceutical
ingredient production.
 For formulations, Dr. Reddy's Laboratories boasts several manufacturing plants
in India. The Formulations Hyderabad Plant, situated at Plot No. 146, IDA
Bollaram, Jinnaram Mandal, Medak District, Telangana 502 320, INDIA, is
dedicated to producing high-quality pharmaceutical formulations.
 Moving east, the Formulations Yanam Plant, nestled in Ward-F, Block-4,
Adavipolam, Yanam, Pondicherry 533 464, INDIA, contributes to the
company's formulations production.
 The Formulations Baddi Plant, located in Village Mauja Thana, Nalagarh
Baddi Road, Baddi, Solan District, Himachal Pradesh 173 205, INDIA, is
another cornerstone in Dr. Reddy's efforts to provide patients with top-
notch pharmaceutical products.

 Additionally, the Formulations Vizag SEZ Plant 1, positioned at Plot No. P1-
P9, Phase III, Duvvada, VSEZ, Visakapatanam, Andhra Pradesh 530 046,
INDIA, further solidifies the company's manufacturing capabilities in the
region.

Map of Manufacturing facilities of the firm.

 Manufacturing in the United States and Mexico

 Dr. Reddy's Laboratories has a significant presence in the United States, marked
by two manufacturing facilities. Dr. Reddy's Laboratories Louisiana LLC, located
at 8800 Line Avenue, Shreveport, Louisiana 71106, USA, contributes to the
company's pharmaceutical manufacturing efforts in North America.

 In Tennessee, Dr. Reddy's Laboratories Tennessee LLC plays a pivotal role.

Positioned at P.O. Box 9002, 201 Industrial Drive, Bristol, Tennessee 37621-
9002, USA, this facility exemplifies the company's commitment to
manufacturing excellence on American soil.

 In addition to these locations, Dr. Reddy's Laboratories has a manufacturing

presence in Mexico. The API Cuernavaca Plant, operated by Industrias Quimicas
Falcon De Mexico S.A. de C.V. and situated at Carretera Federal Cuernavaca-
Cuautla, KM 4.5 CIVAC, Jiutepec, Morelos, Mexico 62578, is a crucial
manufacturing hub that complements the company's global manufacturing
network.++
 PRODUCTS OF THE FIRM:

Dr. Reddy's Laboratories manufactures a wide range of pharmaceutical

products, including generic medicines, active pharmaceutical ingredients (APIs),
and proprietary formulations.

The company's product portfolio spans various therapeutic categories and

serves patients in numerous countries. Here are some of the types of products
made by Dr. Reddy's: Generic Pharmaceuticals:

Dr. Reddy's is known for its extensive portfolio of generic pharmaceuticals.

These are non-branded versions of existing medications, providing affordable
alternatives to branded drugs.

Generic products cover a wide range of therapeutic areas, including

cardiovascular, anti-infective, central nervous system, gastrointestinal, and
more.
Active Pharmaceutical Ingredients (APIs): Dr. Reddy's manufactures APIs,
which are the essential chemical compounds used as the active ingredients in
pharmaceutical formulations. These APIs are used not only for the company's
proprietary formulations but are also supplied to other pharmaceutical
companies worldwide.

Branded Formulations: In addition to generics, Dr. Reddy's develops and

markets branded pharmaceutical formulations. These are proprietary
medications developed by the company, often with a focus on niche therapeutic
areas or innovative drug delivery systems. Branded formulations include
medications for chronic diseases, pain management, and more.

Biosimilars: Dr. Reddy's has ventured into the production of biosimilars, which
are biologic drugs that are highly similar to existing biologic medicines. These
biosimilars offer effective treatments for various conditions, including
autoimmune diseases and cancer.
Over-the-Counter (OTC) Products: Dr. Reddy's manufactures and markets a
range of OTC products, including vitamins, dietary supplements, and common
remedies for minor ailments. These products are typically available without a
prescription.
Diagnostic Kits: The company also produces diagnostic kits used in medical
testing and diagnosis. These kits are essential tools for healthcare professionals
and laboratories. Critical Care Products: Dr. Reddy's manufactures critical care
medications and therapies for patients in intensive care units and those with
severe medical conditions. These products are vital for patient care in hospitals.

Biotechnology Products: Dr. Reddy's has ventured into the biotechnology

field, developing biopharmaceutical products, including biosimilars and other
innovative biologics.